Screener
Royalty Pharma RPRX Impairment Charges
Impairment Charges at other companies
Other financials
Where this comes from
Reported directly by Royalty Pharma in its filing.
Tagged under the XBRL concept us-gaap:AssetImpairmentCharges.
The source filing: Royalty Pharma’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 9:02 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001802768-26-000015
| Line item | For the Three Months Ended June 30, 2026 | For the Three Months Ended June 30, 2025 | For the Six Months Ended June 30, 2026 | For the Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Provision for credit losses on unfunded commitments | 13,068 | 92,535 | 9,368 | 92,535 |
| Research and development funding expense | 97,851 | 300,500 | 137,641 | 351,000 |
| General and administrative expenses (includes $107,356 and $91,044 of share-based compensation expense for the three months ended June 30, 2026 and 2025, respectively, and $229,648 and $91,747 for the six months ended June 30, 2026 and 2025, respectively; see Note 4) | 161,887 | 179,769 | 321,377 | 290,475 |
| Financial royalty asset impairment | — | — | 69,443 | — |
| Total operating expense, net | 541,022 | 368,866 | 608,561 | 402,932 |
| Operating income | 133,119 | 209,799 | 696,156 | 743,980 |
| Other (income)/expense | ||||
| Equity in earnings of equity method investees | (4,077) | (2,693) | (25,835) | (9,136) |
Item 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
FAQ
- What is Royalty Pharma's impairment charges?
- Royalty Pharma (RPRX) reported impairment charges of $0 in Q2 2026.
- What does impairment charges mean?
- Write-downs of long-lived assets (excluding goodwill) when their carrying value exceeds fair value, including property, equipment, right-of-use assets, and other tangible assets.
Ask your AI about Royalty Pharma's impairment charges.
Connect your AI assistant and see it in context, right in your chat.
Connect your AI
Claude